呼出气、肺泡气一氧化氮在间质性肺疾病中的研究进展

doi:10.12114/j.issn.1007-9572.2025.0161

摘要/Abstract

摘要： 间质性肺疾病（ILD）是一组包含200多种不同病理类型的异质性肺疾病，因其早期症状较隐匿且临床表现缺乏特异性，诊断和治疗具有挑战性。呼出气一氧化氮（eNO）作为呼出气体中的生物标志物，优势是便捷、无创，可重复操作。本文从一氧化氮（NO）的生物学作用及ILD的发病机制出发，介绍了NO与ILD的联系，系统、全面地归纳了既往呼出气一氧化氮检测（FeNO）及肺泡气一氧化氮检测（CaNO）在各类ILD中的应用，包括在疾病辅助诊断中的价值，在疾病严重程度及预后评估中的价值，以及各亚型间鉴别中的价值，为ILD的诊断及治疗研究提供了新的思路。

关键词: 间质性肺疾病, 结缔组织疾病相关性间质性肺疾病, 特发性肺纤维化, 呼出气一氧化氮, 肺泡气一氧化氮, 综述

Abstract:

Interstitial lung disease (ILD) is a group of heterogeneous lung diseases containing more than 200 different pathological types. Due to its insidious early symptoms and lack of specificity in clinical manifestations, diagnosis and treatment are challenging. Exhaled nitric oxide (eNO), as a biomarker in exhaled gas, has the advantages of being convenient, non-invasive and repeatable. This article starts from the biological role of nitric oxide and the pathogenesis of interstitial lung diseases, introduces the connection between NO and interstitial lung diseases, systematically and comprehensively summarizes the application of fractional exhaled nitric oxide (FeNO) and alveolar nitric oxide (CaNO) in various interstitial lung diseases in the past few years, including their value in the auxiliary diagnosis of diseases. The value in the assessment of disease severity and prognosis, as well as the value in the differentiation among various subtypes, provides new ideas for the diagnosis and treatment research of interstitial lung diseases.

Key words: Interstitial lung disease, Connective tissue disease-associated interstitial lung disease, Idiopathic pulmonary fibrosis, Exhaled nitric oxide, Alveolar nitric oxide, Review

张明悦,侯艳. 呼出气、肺泡气一氧化氮在间质性肺疾病中的研究进展[J]. 中国全科医学, 2026, 29(18): 2571-2576. DOI: 10.12114/j.issn.1007-9572.2025.0161.
ZHANG Mingyue,HOU Yan. Research Progress of Exhaled Nitric Oxide and Alveolar Nitric Oxide in Interstitial Lung Diseases[J]. Chinese General Practice, 2026, 29(18): 2571-2576. DOI: 10.12114/j.issn.1007-9572.2025.0161.

参考文献 50

[1]	MUDAWI D, HEYES K, HASTINGS R, et al. An update on interstitial lung disease[J]. Br J Hosp Med(Lond), 2021, 82(7): 1-14. DOI: 10.12968/hmed.2020.0556.
[2]	郭鑫龙, 赵志伟, 庞桂芬, 等. 红细胞体积分布宽度变异系数和血清IL-11、IL-31在间质性肺疾病诊断中的应用价值[J]. 解放军医学杂志, 2024, 49(11): 1295-1301.
[3]	黄慧. 间质性肺疾病年度进展2023[J]. 中华结核和呼吸杂志, 2024, 47(1): 44-49.
[4]	LOEWENTHAL L, MENZIES-GOW A. FeNO in asthma[J]. Semin Respir Crit Care Med, 2022, 43(5): 635-645. DOI: 10.1055/s-0042-1743290.
[5]	RAGNOLI B, RADAELI A, POCHETTI P, et al. Fractional nitric oxide measurement in exhaled air(FeNO): perspectives in the management of respiratory diseases[J]. Ther Adv Chronic Dis, 2023, 14: 20406223231190480. DOI: 10.1177/20406223231190480.
[6]	ANAVI S, TIROSH O. iNOS as a metabolic enzyme under stress conditions[J]. Free Radic Biol Med, 2020, 146: 16-35.
[7]	HOYTE F C L, GROSS L M, KATIAL R K. Exhaled nitric oxide: an update[J]. Immunol Allergy Clin North Am, 2018, 38(4): 573-585.
[8]	SOUNDARARAJAN L, DHARMARAJAN A, SAMJI P. Regulation of pleiotropic physiological roles of nitric oxide signaling[J]. Cell Signal, 2023, 101: 110496. DOI: 10.1016/j.cellsig.2022.110496.
[9]	中国医药教育协会慢性气道疾病专业委员会, 中国哮喘联盟. 呼出气一氧化氮检测及其在气道疾病诊治中应用的中国专家共识[J]. 中华医学杂志, 2021, 101(38): 3092-3114.
[10]	ZHANG L, ZHANG M R, AIERKEN A, et al. Role of alveolar nitric oxide in gastroesophageal reflux-associated cough: prospective observational study[J]. Ther Adv Respir Dis, 2024, 18: 17534666241231117. DOI: 10.1177/17534666241231117.
[11]	ZHENG S Y, CHEN S, HU Y, et al. Alveolar nitric oxide concentration plays an important role in identifying cough variant asthma and assessing asthma control in children[J]. J Asthma, 2024, 61(4): 328-337. DOI: 10.1080/02770903.2023.2272806.
[12]	WIJSENBEEK M, SUZUKI A, MAHER T M. Interstitial lung diseases[J]. Lancet, 2022, 400(10354): 769-786.
[13]	LI A H, WU S Y, LI Q, et al. Elucidating the molecular pathways and therapeutic interventions of gaseous mediators in the context of fibrosis[J]. Antioxidants(Basel), 2024, 13(5): 515.
[14]	OTOUPALOVA E, SMITH S, CHENG G J, et al. Oxidative stress in pulmonary fibrosis[J]. Compr Physiol, 2020, 10(2): 509-547. DOI: 10.1002/cphy.c190017.
[15]	CAMELI P, CARLEO A, BERGANTINI L, et al. Oxidant/antioxidant disequilibrium in idiopathic pulmonary fibrosis pathogenesis[J]. Inflammation, 2020, 43(1): 1-7. DOI: 10.1007/s10753-019-01059-1.
[16]	ANDRABI S M, SHARMA N S, KARAN A, et al. Nitric oxide: physiological functions, delivery, and biomedical applications[J]. Adv Sci(Weinh), 2023, 10(30): e2303259. DOI: 10.1002/advs.202303259.
[17]	PAGKOPOULOU E, SOULAIDOPOULOS S, KATSIKI N, et al. The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study[J]. Clin Rheumatol, 2023, 42(4): 1077-1085.
[18]	KHAZRI O, MEZNI A, LIMAM F, et al. Bleomycin-induced damage in rat lung: protective effect of grape seed and skin extract[J]. Dose Response, 2022, 20(4): 15593258221131648. DOI: 10.1177/15593258221131648.
[19]	OGOSHI T, YATERA K, MUKAE H, et al. Role of nitric oxide synthases in respiratory health and disease: insights from triple nitric oxide synthases knockout mice[J]. Int J Mol Sci, 2024, 25(17): 9317. DOI: 10.3390/ijms25179317.
[20]	JOY G M, ARBIV O A, WONG C K, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis[J]. Eur Respir Rev, 2023, 32(167): 220210. DOI: 10.1183/16000617.0210-2022.
[21]	BUKIRI H, VOLKMANN E R. Current advances in the treatment of systemic sclerosis[J]. Curr Opin Pharmacol, 2022, 64: 102211. DOI: 10.1016/j.coph.2022.102211.
[22]	DISTLER O, HIGHLAND K B, GAHLEMANN M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease[J]. N Engl J Med, 2019, 380(26): 2518-2528. DOI: 10.1056/NEJMoa1903076.
[23]	WUTTGE D M, BOZOVIC G, HESSELSTRAND R, et al. Increased alveolar nitric oxide in early systemic sclerosis[J]. Clin Exp Rheumatol, 2010, 28(5 Suppl 62): S5-S9.
[24]	BENFANTE A, MESSINA R, PATERNÒ A, et al. Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis[J]. Minerva Med, 2018, 109(2): 71-78. DOI: 10.23736/S0026-4806.17.05285-5.
[25]	HOANG-DUC H, PHAM-HUY Q, VU-MINH T, et al. Study of the correlation between HRCT semi-quantitative scoring, concentration of alveolar nitric oxide, and clinical-functional parameters of systemic sclerosis-induced interstitial lung disease[J]. Yale J Biol Med, 2020, 93(5): 657-667.
[26]	ZHENG Y, LOU Y Y, ZHU F, et al. Utility of fractional exhaled nitric oxide in interstitial lung disease[J]. J Breath Res, 2021, 15(3): 036004(8pp). DOI: 10.1088/1752-7163/ac01c1.WEITOFT T, LIND A, LARSSON A, et al. Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment[J]. Sci Rep, 2022, 12(1): 6489. DOI: 10.1038/s41598-022-10334-5.
[27]	PODOLANCZUK A J, WONG A W, SAITO S, et al. Update in interstitial lung disease 2020[J]. Am J Respir Crit Care Med, 2021, 203(11): 1343-1352. DOI: 10.1164/rccm.202103-0559UP.
[28]	韩晓静, 韩齐齐, 钱峰. 特发性肺纤维化的炎症机制与潜在药物靶标[J]. 中国药理学通报, 2024, 40(5): 828-832.
[29]	CAMELI P, BERGANTINI L, SALVINI M, et al. Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis[J]. Nitric Oxide, 2019, 89: 41-45.
[30]	KOTECHA J, SHULGINA L, SEXTON D W, et al. Plasma vascular endothelial growth factor concentration and alveolar nitric oxide as potential predictors of disease progression and mortality in idiopathic pulmonary fibrosis[J]. J Clin Med, 2016, 5(9): 80.
[31]	CAMELI P, BERGANTINI L, D'ALESSANDRO M, et al. Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis[J]. Minerva Med, 2020, 111(4): 324-329.
[32]	KRAUSS E, FROEHLER M, DEGEN M, et al. Exhalative breath markers do not offer for diagnosis of interstitial lung diseases: data from the European IPF registry(eurIPFreg) and biobank[J]. J Clin Med, 2019, 8(5): 643. DOI: 10.3390/jcm8050643.
[33]	CAMELI P, BARBAGLI E, ROTTOLI P. Exhaled nitric oxide is not increased in pulmonary sarcoidosis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2016, 33(1): 39-40.
[34]	LEVRA S, GIANNOCCARO F, CHERNOVSKY M, et al. Alveolar nitric oxide concentration as a potential biomarker of fibrosis and active disease in pulmonary sarcoidosis: a pilot study[J]. J Breath Res, 2025, 19(2): 10.1088/1752-7163/adac82. DOI: 10.1088/1752-7163/adac82.
[35]	CHURG A. Hypersensitivity pneumonitis: new concepts and classifications[J]. Mod Pathol, 2022, 35(Suppl 1): 15-27. DOI: 10.1038/s41379-021-00866-y.
[36]	GUILLEMINAULT L, SAINT-HILAIRE A, FAVELLE O, et al. Can exhaled nitric oxide differentiate causes of pulmonary fibrosis?[J]. Respir Med, 2013, 107(11): 1789-1796. DOI: 10.1016/j.rmed.2013.07.007.
[37]	OJANGUREN I, CRUZ M J, VILLAR A, et al. Utility of exhaled nitric oxide fraction for the diagnosis of hypersensitivity pneumonitis[J]. Lung, 2016, 194(1): 75-80. DOI: 10.1007/s00408-015-9824-5.
[38]	OISHI K, HIRANO T, SUETAKE R, et al. Exhaled nitric oxide measurements in patients with acute-onset interstitial lung disease[J]. J Breath Res, 2017, 11(3): 036001.
[39]	SPAGNOLO P, RYERSON C J, GULER S, et al. Occupational interstitial lung diseases[J]. J Intern Med, 2023, 294(6): 798-815. DOI: 10.1111/joim.13707.
[40]	SCALIA CARNEIRO A P, ALGRANTI E, CHÉROT-KORNOBIS N, et al. Inflammatory and oxidative stress biomarkers induced by silica exposure in crystal craftsmen[J]. Am J Ind Med, 2020, 63(4): 337-347. DOI: 10.1002/ajim.23088.
[41]	KOSKELA K, OKSA P, SAUNI R, et al. Pulmonary inflammation in foundry workers[J]. J Occup Environ Med, 2015, 57(2): 124-128. DOI: 10.1097/JOM.0000000000000390.
[42]	COTTIN V. Eosinophilic lung diseases[J]. Immunol Allergy Clin North Am, 2023, 43(2): 289-322. DOI: 10.1016/j.iac.2023.01.002.
[43]	MAHER T M. Interstitial lung disease: a review[J]. JAMA, 2024, 331(19): 1655-1665. DOI: 10.1001/jama.2024.3669.
[44]	张凤芹, 窦欣然, 张惠兰. 新型冠状病毒感染后间质性肺疾病[J]. 中国实用内科杂志, 2023, 43(9): 714-717.
[45]	MANISCALCO M, AMBROSINO P, POTO R, et al. Can FeNO be a biomarker in the post-COVID-19 patients monitoring?[J]. Respir Med, 2022, 193: 106745. DOI: 10.1016/j.rmed.2022.106745.
[46]	CAMELI P, BARGAGLI E, BERGANTINI L, et al. Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: a pivotal study[J]. Antioxidants(Basel), 2021, 10(9): 1350.
[47]	HUA-HUY T, GÜNTHER S, LORUT C, et al. Distal lung inflammation assessed by alveolar concentration of nitric oxide is an individualised biomarker of severe COVID-19 pneumonia[J]. J Pers Med, 2022, 12(10): 1631. DOI: 10.3390/jpm12101631.
[48]	CAMELI P, BARGAGLI E, BERGANTINI L, et al. Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease[J]. J Breath Res, 2019, 13(2): 026008. DOI: 10.1088/1752-7163/ab0233.
[49]	RIZZI M, RADOVANOVIC D, AIROLDI A, et al. Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients[J]. Clin Exp Rheumatol, 2019, 37 Suppl 119(4): 125-132.
[50]	常潇丹, 陈美佳, 廖画, 等.肺泡一氧化氮在间质性肺疾病诊断及鉴别中的应用价值[J].南方医科大学学报, 2023, 43(8): 1410-1416. DOI: 10.12122/j.issn.1673-4254.2023.08.19.